Tadalafil
Product Images NDC 50090-4276

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 50090-4276). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500904276)

FDA Label Image

Tadalafil-fig1 (Tadalafil Fig1)

The text appears to be describing a graph (Figure 1), which shows the mean change in blood pressure in response to sublingual nitroglycerin at various time intervals after taking either Tadalafil or a placebo. The graph displays the difference between standing systolic blood pressure, standing diastolic blood pressure, supine systolic blood pressure, and supine diastolic blood pressure. The point estimate with a 90% confidence interval is also shown.*

FDA Label Image

Tadalafil-fig2 (Tadalafil Fig2)

This is a description of a study that involves the administration of Tadalafil and Doxazosin, with the dosage of Tadalafil being 20 mg and the dosage of Doxazosin being 8 mg. A placebo and Doxazosin at 8 mg were also administered. The study measured the mean change in systolic blood pressure over time after the administration of Doxazosin.*

FDA Label Image

Tadalafil-fig3 (Tadalafil Fig3)

This is a report from a study involving the use of 20mg of tadalafil and 8mg of doxazosin at different times throughout the day. The study measures the mean change from a time-matched baseline in systolic blood pressure. The text is not available for the figure produced.*

FDA Label Image

Tadalafil-fig4 (Tadalafil Fig4)

Plasma concentration of Tadalafil (a medication used to treat erectile dysfunction) is shown in this figure. The graph illustrates the concentration levels after administering a single dose of 20mg and once daily multiple doses of 5mg for five consecutive days. The x-axis displays the time in hours while the y-axis represents the concentration in mg/L. Error bars are shown for each data point to indicate variability.*

FDA Label Image

Tadalafil-fig5.jpg (Tadalafil Fig5)

This is a figure from Study J which compares the mean changes in IPSS total score in BPH patients by visit. The treatment duration in weeks is also shown on the X-axis. The medications being compared are Tatalafil 5 mg and placebo. No further information is available.*

FDA Label Image

Tadalafil-fig6.jpg (Tadalafil Fig6)

FDA Label Image

Tadalafil-fig7.jpg (Tadalafil Fig7)

The text describes a figure (Figure 7) showing the mean total IPSS changes by visit in patients with BPH taking Tadalafil and Finasteride for once-daily use. The figure shows the weeks of therapy along with the LS mean change from baseline, and indicates that the treatment difference is significant (p<0.001).*

FDA Label Image

Tadalafil-fig8.jpg (Tadalafil Fig8)

FDA Label Image

Tadalafil-str (Tadalafil Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.